Gastroenterology · Venice, FL
NPI
1528139086
Since 2006
Specialty
Gastroenterology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1370 E Venice Ave, Suite 210
Venice, FL, 34285
Phone (941) 584-6272
Groups this clinician bills Medicare through
Medicare paid, 2024
$378K
4,934 services
Medicare patients, 2024
1,086
Average age 74
Drug cost, 2024
$1.8M
1,983 prescriptions
Company payments, 2025
$2,043
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ronald W Demasi was code 99439 (chronic, principal, and transitional care management), 1,229 times for 118 patients. In total Ronald W Demasi billed 4,934 services in 48 codes, and Medicare paid $378K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-12-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99439 Chronic, Principal, and Transitional Care Management | Office | 1,229 | 118 | $37.77 | $46K |
| 99214 Office E&M - Established | Office | 1,011 | 619 | $96.82 | $98K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 700 | 118 | $48.98 | $34K |
| 99204 Office E&M - New | Office | 321 | 321 | $122.18 | $39K |
| 45380 Lower GI Endoscopy - Other | Facility | 221 | 218 | $121.90 | $27K |
| 43239 Upper GI Endoscopy | Facility | 215 | 212 | $61.32 | $13K |
| 99213 Office E&M - Established | Office | 116 | 104 | $65.63 | $7,614 |
| 97110 PT Treatment | Office | 107 | 20 | $19.56 | $2,093 |
| 99454 E&M - Miscellaneous | Office | 98 | 14 | $35.32 | $3,461 |
| 76981 Ultrasound - Nonspecific | Office | 85 | 80 | $74.72 | $6,351 |
| 45385 Colonoscopy - Lesion Removal | Facility | 84 | 84 | $210.74 | $18K |
| 99457 E&M - Miscellaneous | Office | 82 | 13 | $37.82 | $3,102 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 75 | 75 | $186.12 | $14K |
| 43249 Upper GI Endoscopy | Facility | 71 | 69 | $108.47 | $7,701 |
| 76700 Ultrasound - Abdomen and Pelvis | Office | 70 | 64 | $84.94 | $5,946 |
By year: 2022 $355K for 4,669 services; 2023 $367K for 4,332 services; 2024 $378K for 4,934 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ronald W Demasi prescribed most often to Medicare patients was Pantoprazole Sodium, with 517 prescriptions and refills. In total Ronald W Demasi wrote 1,983 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 517 | 1,177 | 212 | $5,184 |
| Omeprazole Generic | 174 | 435 | 69 | $2,041 |
| Famotidine Generic | 149 | 337 | 66 | $1,683 |
| Mesalamine Generic | 93 | 195 | 27 | $33K |
| Budesonide Dr Budesonide | 70 | 94 | 32 | $4,311 |
| Linzess Linaclotide | 64 | 97 | 19 | $51K |
| Dexlansoprazole Dr Dexlansoprazole | 41 | 95 | 17 | $14K |
| Stelara Ustekinumab | 40 | 55 | Under 11 | $998K |
| Dicyclomine Hcl Generic | 40 | 77 | 18 | $668 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 39 | 39 | 25 | $371 |
| Budesonide Ec Budesonide | 37 | 72 | 21 | $7,965 |
| Prednisone Generic | 35 | 37 | 17 | $169 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 34 | 42 | 15 | $425 |
| Ondansetron Odt Ondansetron | 32 | 36 | 19 | $721 |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 29 | 29 | 29 | $4,669 |
Brand drugs: - claims; generic drugs: 1,598 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ronald W Demasi $2,043 ($2,043 in general payments such as food, travel and fees) from 18 companies. The largest payer was Janssen Biotech, Inc. with $559.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 8 | $559 |
| Medtronic, Inc. MDT | 3 | $410 |
| Madrigal Pharmaceuticals MDGL | 4 | $219 |
| Fujifilm Healthcare Americas Corporation | 1 | $159 |
| Pfizer Inc. PFE | 7 | $107 |
| Abbvie Inc. ABBV | 3 | $90.44 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $83.72 |
| Gilead Sciences, Inc. GILD | 3 | $73.85 |
| Braintree Laboratories, Inc. | 3 | $67.5 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 3 | $59.43 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.